nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ALB—multiple sclerosis	0.171	1	CbGaD
Gefitinib—ABCG2—Cladribine—multiple sclerosis	0.058	0.129	CbGbCtD
Gefitinib—ABCG2—Mitoxantrone—multiple sclerosis	0.0423	0.0941	CbGbCtD
Gefitinib—CYP2D6—Fingolimod—multiple sclerosis	0.0306	0.068	CbGbCtD
Gefitinib—ALB—Prednisone—multiple sclerosis	0.0242	0.0539	CbGbCtD
Gefitinib—ABCG2—Dexamethasone—multiple sclerosis	0.0219	0.0488	CbGbCtD
Gefitinib—ABCB1—Methylprednisolone—multiple sclerosis	0.0209	0.0465	CbGbCtD
Gefitinib—CYP1A1—Dexamethasone—multiple sclerosis	0.0203	0.045	CbGbCtD
Gefitinib—CYP3A4—Fingolimod—multiple sclerosis	0.0195	0.0433	CbGbCtD
Gefitinib—ABCG2—Methotrexate—multiple sclerosis	0.0176	0.0392	CbGbCtD
Gefitinib—CYP2C19—Prednisone—multiple sclerosis	0.0157	0.0349	CbGbCtD
Gefitinib—ABCB1—Mitoxantrone—multiple sclerosis	0.0153	0.0339	CbGbCtD
Gefitinib—ABCB1—Betamethasone—multiple sclerosis	0.0136	0.0302	CbGbCtD
Gefitinib—ABCB1—Prednisolone—multiple sclerosis	0.0134	0.0298	CbGbCtD
Gefitinib—ABCB1—Prednisone—multiple sclerosis	0.0127	0.0282	CbGbCtD
Gefitinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0125	0.0279	CbGbCtD
Gefitinib—CYP3A5—Dexamethasone—multiple sclerosis	0.0122	0.027	CbGbCtD
Gefitinib—ALB—Methotrexate—multiple sclerosis	0.0122	0.027	CbGbCtD
Gefitinib—CYP2C19—Dexamethasone—multiple sclerosis	0.00981	0.0218	CbGbCtD
Gefitinib—CYP3A4—Triamcinolone—multiple sclerosis	0.0095	0.0211	CbGbCtD
Gefitinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00915	0.0203	CbGbCtD
Gefitinib—CYP2C9—Dexamethasone—multiple sclerosis	0.00816	0.0181	CbGbCtD
Gefitinib—CYP3A4—Betamethasone—multiple sclerosis	0.00815	0.0181	CbGbCtD
Gefitinib—CYP3A4—Prednisolone—multiple sclerosis	0.00804	0.0179	CbGbCtD
Gefitinib—ABCB1—Dexamethasone—multiple sclerosis	0.00791	0.0176	CbGbCtD
Gefitinib—CYP3A4—Prednisone—multiple sclerosis	0.0076	0.0169	CbGbCtD
Gefitinib—CYP2D6—Dexamethasone—multiple sclerosis	0.00746	0.0166	CbGbCtD
Gefitinib—ABCB1—Methotrexate—multiple sclerosis	0.00636	0.0141	CbGbCtD
Gefitinib—ERBB3—peripheral nervous system—multiple sclerosis	0.00494	0.0626	CbGeAlD
Gefitinib—CYP3A4—Dexamethasone—multiple sclerosis	0.00474	0.0105	CbGbCtD
Gefitinib—SBK1—retina—multiple sclerosis	0.00299	0.0379	CbGeAlD
Gefitinib—Bosutinib—MERTK—multiple sclerosis	0.00271	0.804	CrCbGaD
Gefitinib—SBK1—medulla oblongata—multiple sclerosis	0.00216	0.0274	CbGeAlD
Gefitinib—SBK1—midbrain—multiple sclerosis	0.00198	0.0251	CbGeAlD
Gefitinib—SBK1—spinal cord—multiple sclerosis	0.00193	0.0244	CbGeAlD
Gefitinib—CSNK1E—retina—multiple sclerosis	0.00165	0.021	CbGeAlD
Gefitinib—SBK1—cerebellum—multiple sclerosis	0.00153	0.0194	CbGeAlD
Gefitinib—MKNK2—retina—multiple sclerosis	0.00152	0.0192	CbGeAlD
Gefitinib—MKNK1—retina—multiple sclerosis	0.0015	0.019	CbGeAlD
Gefitinib—EPHA6—nervous system—multiple sclerosis	0.00127	0.0161	CbGeAlD
Gefitinib—SBK1—brain—multiple sclerosis	0.00124	0.0157	CbGeAlD
Gefitinib—HIPK4—brain—multiple sclerosis	0.00123	0.0156	CbGeAlD
Gefitinib—EPHA6—central nervous system—multiple sclerosis	0.00122	0.0155	CbGeAlD
Gefitinib—CSNK1E—medulla oblongata—multiple sclerosis	0.0012	0.0151	CbGeAlD
Gefitinib—IRAK4—medulla oblongata—multiple sclerosis	0.00118	0.0149	CbGeAlD
Gefitinib—MAP3K19—nervous system—multiple sclerosis	0.00115	0.0146	CbGeAlD
Gefitinib—MAP2K5—brainstem—multiple sclerosis	0.00114	0.0145	CbGeAlD
Gefitinib—MAP3K19—central nervous system—multiple sclerosis	0.00111	0.0141	CbGeAlD
Gefitinib—MKNK2—medulla oblongata—multiple sclerosis	0.0011	0.0139	CbGeAlD
Gefitinib—CSNK1E—midbrain—multiple sclerosis	0.00109	0.0138	CbGeAlD
Gefitinib—MKNK1—medulla oblongata—multiple sclerosis	0.00108	0.0137	CbGeAlD
Gefitinib—CHEK2—brain—multiple sclerosis	0.00108	0.0137	CbGeAlD
Gefitinib—CSNK1E—spinal cord—multiple sclerosis	0.00107	0.0135	CbGeAlD
Gefitinib—ERBB3—midbrain—multiple sclerosis	0.00105	0.0134	CbGeAlD
Gefitinib—IRAK4—spinal cord—multiple sclerosis	0.00105	0.0133	CbGeAlD
Gefitinib—ERBB3—spinal cord—multiple sclerosis	0.00103	0.013	CbGeAlD
Gefitinib—MKNK2—midbrain—multiple sclerosis	0.001	0.0127	CbGeAlD
Gefitinib—IRAK1—midbrain—multiple sclerosis	0.001	0.0127	CbGeAlD
Gefitinib—MKNK1—midbrain—multiple sclerosis	0.00099	0.0125	CbGeAlD
Gefitinib—MKNK2—spinal cord—multiple sclerosis	0.000978	0.0124	CbGeAlD
Gefitinib—EPHA6—brain—multiple sclerosis	0.000971	0.0123	CbGeAlD
Gefitinib—MKNK1—spinal cord—multiple sclerosis	0.000966	0.0122	CbGeAlD
Gefitinib—CSNK1E—nervous system—multiple sclerosis	0.000898	0.0114	CbGeAlD
Gefitinib—IRAK4—nervous system—multiple sclerosis	0.000884	0.0112	CbGeAlD
Gefitinib—MAP3K19—brain—multiple sclerosis	0.000883	0.0112	CbGeAlD
Gefitinib—EGFR—cerebellum—multiple sclerosis	0.000879	0.0111	CbGeAlD
Gefitinib—ERBB3—nervous system—multiple sclerosis	0.000867	0.011	CbGeAlD
Gefitinib—CSNK1E—central nervous system—multiple sclerosis	0.000865	0.011	CbGeAlD
Gefitinib—IRAK4—central nervous system—multiple sclerosis	0.000851	0.0108	CbGeAlD
Gefitinib—CSNK1E—cerebellum—multiple sclerosis	0.000845	0.0107	CbGeAlD
Gefitinib—ERBB3—central nervous system—multiple sclerosis	0.000834	0.0106	CbGeAlD
Gefitinib—IRAK4—cerebellum—multiple sclerosis	0.000832	0.0105	CbGeAlD
Gefitinib—MKNK2—nervous system—multiple sclerosis	0.000824	0.0104	CbGeAlD
Gefitinib—ERBB3—cerebellum—multiple sclerosis	0.000816	0.0103	CbGeAlD
Gefitinib—MKNK1—nervous system—multiple sclerosis	0.000814	0.0103	CbGeAlD
Gefitinib—MAP2K5—medulla oblongata—multiple sclerosis	0.000796	0.0101	CbGeAlD
Gefitinib—MKNK2—central nervous system—multiple sclerosis	0.000793	0.0101	CbGeAlD
Gefitinib—MKNK1—central nervous system—multiple sclerosis	0.000783	0.00992	CbGeAlD
Gefitinib—MKNK2—cerebellum—multiple sclerosis	0.000775	0.00982	CbGeAlD
Gefitinib—IRAK1—cerebellum—multiple sclerosis	0.000775	0.00982	CbGeAlD
Gefitinib—MKNK1—cerebellum—multiple sclerosis	0.000766	0.0097	CbGeAlD
Gefitinib—MAP2K5—midbrain—multiple sclerosis	0.000728	0.00922	CbGeAlD
Gefitinib—EGFR—brain—multiple sclerosis	0.000714	0.00904	CbGeAlD
Gefitinib—MAP2K5—spinal cord—multiple sclerosis	0.00071	0.009	CbGeAlD
Gefitinib—CSNK1E—brain—multiple sclerosis	0.000686	0.0087	CbGeAlD
Gefitinib—IRAK4—brain—multiple sclerosis	0.000676	0.00856	CbGeAlD
Gefitinib—STK10—nervous system—multiple sclerosis	0.00067	0.00849	CbGeAlD
Gefitinib—ERBB3—brain—multiple sclerosis	0.000662	0.00839	CbGeAlD
Gefitinib—STK10—central nervous system—multiple sclerosis	0.000645	0.00817	CbGeAlD
Gefitinib—STK10—cerebellum—multiple sclerosis	0.000631	0.00799	CbGeAlD
Gefitinib—MKNK2—brain—multiple sclerosis	0.00063	0.00798	CbGeAlD
Gefitinib—IRAK1—brain—multiple sclerosis	0.00063	0.00798	CbGeAlD
Gefitinib—MKNK1—brain—multiple sclerosis	0.000622	0.00788	CbGeAlD
Gefitinib—MAP2K5—nervous system—multiple sclerosis	0.000598	0.00758	CbGeAlD
Gefitinib—ORM1—spinal cord—multiple sclerosis	0.000577	0.0073	CbGeAlD
Gefitinib—MAP2K5—central nervous system—multiple sclerosis	0.000576	0.0073	CbGeAlD
Gefitinib—MAP2K5—cerebellum—multiple sclerosis	0.000563	0.00713	CbGeAlD
Gefitinib—STK10—brain—multiple sclerosis	0.000512	0.00649	CbGeAlD
Gefitinib—ORM1—nervous system—multiple sclerosis	0.000486	0.00615	CbGeAlD
Gefitinib—ORM1—central nervous system—multiple sclerosis	0.000468	0.00593	CbGeAlD
Gefitinib—CSNK1E—Danazol—Prednisone—multiple sclerosis	0.000462	0.123	CbGdCrCtD
Gefitinib—MAP2K5—brain—multiple sclerosis	0.000457	0.00579	CbGeAlD
Gefitinib—Erlotinib—ALB—multiple sclerosis	0.0004	0.118	CrCbGaD
Gefitinib—ABCG2—medulla oblongata—multiple sclerosis	0.000387	0.00491	CbGeAlD
Gefitinib—CYP2D6—brainstem—multiple sclerosis	0.000381	0.00482	CbGeAlD
Gefitinib—ABCG2—midbrain—multiple sclerosis	0.000354	0.00449	CbGeAlD
Gefitinib—ABCG2—spinal cord—multiple sclerosis	0.000345	0.00438	CbGeAlD
Gefitinib—ALB—brain—multiple sclerosis	0.000326	0.00412	CbGeAlD
Gefitinib—CSNK1E—Betamethasone—Methylprednisolone—multiple sclerosis	0.000323	0.0858	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000323	0.0858	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Dexamethasone—multiple sclerosis	0.000318	0.0844	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Betamethasone—multiple sclerosis	0.000318	0.0844	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Triamcinolone—multiple sclerosis	0.000311	0.0825	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Triamcinolone—multiple sclerosis	0.000311	0.0825	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Prednisone—multiple sclerosis	0.000295	0.0783	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—multiple sclerosis	0.000295	0.0783	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisolone—multiple sclerosis	0.000288	0.0764	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Prednisolone—multiple sclerosis	0.000288	0.0764	CbGdCrCtD
Gefitinib—CYP1A1—nervous system—multiple sclerosis	0.000276	0.0035	CbGeAlD
Gefitinib—ABCG2—cerebellum—multiple sclerosis	0.000274	0.00347	CbGeAlD
Gefitinib—CYP1A1—central nervous system—multiple sclerosis	0.000266	0.00337	CbGeAlD
Gefitinib—ABCB1—retina—multiple sclerosis	0.000264	0.00335	CbGeAlD
Gefitinib—Vandetanib—ALB—multiple sclerosis	0.000263	0.078	CrCbGaD
Gefitinib—Epistaxis—Triamcinolone—multiple sclerosis	0.000261	0.0018	CcSEcCtD
Gefitinib—Dry skin—Prednisone—multiple sclerosis	0.00026	0.00179	CcSEcCtD
Gefitinib—Malaise—Mitoxantrone—multiple sclerosis	0.000258	0.00178	CcSEcCtD
Gefitinib—Hypokalaemia—Prednisone—multiple sclerosis	0.000258	0.00178	CcSEcCtD
Gefitinib—Asthenia—Cladribine—multiple sclerosis	0.000255	0.00176	CcSEcCtD
Gefitinib—Weight decreased—Betamethasone—multiple sclerosis	0.000254	0.00175	CcSEcCtD
Gefitinib—Weight decreased—Dexamethasone—multiple sclerosis	0.000254	0.00175	CcSEcCtD
Gefitinib—Pruritus—Cladribine—multiple sclerosis	0.000251	0.00173	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Methotrexate—multiple sclerosis	0.000251	0.00173	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.00025	0.00172	CcSEcCtD
Gefitinib—Cough—Mitoxantrone—multiple sclerosis	0.00025	0.00172	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000249	0.00172	CcSEcCtD
Gefitinib—Haemoglobin—Triamcinolone—multiple sclerosis	0.000249	0.00172	CcSEcCtD
Gefitinib—Haemoglobin—Methylprednisolone—multiple sclerosis	0.000249	0.00172	CcSEcCtD
Gefitinib—Haemorrhage—Triamcinolone—multiple sclerosis	0.000248	0.00171	CcSEcCtD
Gefitinib—Haemorrhage—Methylprednisolone—multiple sclerosis	0.000247	0.00171	CcSEcCtD
Gefitinib—Conjunctivitis—Betamethasone—multiple sclerosis	0.000244	0.00168	CcSEcCtD
Gefitinib—Conjunctivitis—Dexamethasone—multiple sclerosis	0.000244	0.00168	CcSEcCtD
Gefitinib—Diarrhoea—Cladribine—multiple sclerosis	0.000243	0.00168	CcSEcCtD
Gefitinib—Arrhythmia—Prednisolone—multiple sclerosis	0.000241	0.00166	CcSEcCtD
Gefitinib—Pancreatitis—Prednisone—multiple sclerosis	0.00024	0.00166	CcSEcCtD
Gefitinib—CHEK2—Danazol—Prednisone—multiple sclerosis	0.000236	0.0628	CbGdCrCtD
Gefitinib—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000236	0.00163	CcSEcCtD
Gefitinib—Infection—Mitoxantrone—multiple sclerosis	0.000232	0.0016	CcSEcCtD
Gefitinib—Eye disorder—Methylprednisolone—multiple sclerosis	0.000231	0.0016	CcSEcCtD
Gefitinib—Shock—Mitoxantrone—multiple sclerosis	0.00023	0.00159	CcSEcCtD
Gefitinib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.00023	0.00158	CcSEcCtD
Gefitinib—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000229	0.00158	CcSEcCtD
Gefitinib—Abdominal pain—Azathioprine—multiple sclerosis	0.000228	0.00158	CcSEcCtD
Gefitinib—Body temperature increased—Azathioprine—multiple sclerosis	0.000228	0.00158	CcSEcCtD
Gefitinib—Skin disorder—Mitoxantrone—multiple sclerosis	0.000227	0.00157	CcSEcCtD
Gefitinib—Haemoglobin—Dexamethasone—multiple sclerosis	0.000226	0.00156	CcSEcCtD
Gefitinib—Haemoglobin—Betamethasone—multiple sclerosis	0.000226	0.00156	CcSEcCtD
Gefitinib—Vomiting—Cladribine—multiple sclerosis	0.000226	0.00156	CcSEcCtD
Gefitinib—Haemorrhage—Dexamethasone—multiple sclerosis	0.000225	0.00155	CcSEcCtD
Gefitinib—Haemorrhage—Betamethasone—multiple sclerosis	0.000225	0.00155	CcSEcCtD
Gefitinib—Angiopathy—Methylprednisolone—multiple sclerosis	0.000224	0.00155	CcSEcCtD
Gefitinib—Rash—Cladribine—multiple sclerosis	0.000224	0.00155	CcSEcCtD
Gefitinib—Dermatitis—Cladribine—multiple sclerosis	0.000224	0.00154	CcSEcCtD
Gefitinib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000223	0.00154	CcSEcCtD
Gefitinib—Anorexia—Mitoxantrone—multiple sclerosis	0.000223	0.00154	CcSEcCtD
Gefitinib—ABCG2—brain—multiple sclerosis	0.000223	0.00282	CbGeAlD
Gefitinib—Arrhythmia—Triamcinolone—multiple sclerosis	0.000222	0.00153	CcSEcCtD
Gefitinib—Weight decreased—Prednisone—multiple sclerosis	0.000221	0.00153	CcSEcCtD
Gefitinib—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000221	0.00153	CcSEcCtD
Gefitinib—Hypotension—Mitoxantrone—multiple sclerosis	0.000218	0.00151	CcSEcCtD
Gefitinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000215	0.00149	CcSEcCtD
Gefitinib—Angioedema—Prednisolone—multiple sclerosis	0.000214	0.00148	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000213	0.00147	CcSEcCtD
Gefitinib—Hypersensitivity—Azathioprine—multiple sclerosis	0.000213	0.00147	CcSEcCtD
Gefitinib—Malaise—Prednisolone—multiple sclerosis	0.000212	0.00146	CcSEcCtD
Gefitinib—CYP1A1—brain—multiple sclerosis	0.000211	0.00268	CbGeAlD
Gefitinib—Nausea—Cladribine—multiple sclerosis	0.000211	0.00146	CcSEcCtD
Gefitinib—Eye disorder—Betamethasone—multiple sclerosis	0.00021	0.00145	CcSEcCtD
Gefitinib—Eye disorder—Dexamethasone—multiple sclerosis	0.00021	0.00145	CcSEcCtD
Gefitinib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000208	0.00144	CcSEcCtD
Gefitinib—Angiopathy—Dexamethasone—multiple sclerosis	0.000204	0.00141	CcSEcCtD
Gefitinib—Angiopathy—Betamethasone—multiple sclerosis	0.000204	0.00141	CcSEcCtD
Gefitinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000203	0.0014	CcSEcCtD
Gefitinib—CYP3A4—nervous system—multiple sclerosis	0.000203	0.00257	CbGeAlD
Gefitinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000201	0.00139	CcSEcCtD
Gefitinib—Arrhythmia—Dexamethasone—multiple sclerosis	0.000201	0.00139	CcSEcCtD
Gefitinib—Arrhythmia—Betamethasone—multiple sclerosis	0.000201	0.00139	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—multiple sclerosis	0.000201	0.00138	CcSEcCtD
Gefitinib—Pain—Mitoxantrone—multiple sclerosis	0.0002	0.00138	CcSEcCtD
Gefitinib—Constipation—Mitoxantrone—multiple sclerosis	0.0002	0.00138	CcSEcCtD
Gefitinib—CYP2D6—nervous system—multiple sclerosis	0.0002	0.00253	CbGeAlD
Gefitinib—Alopecia—Dexamethasone—multiple sclerosis	0.000199	0.00137	CcSEcCtD
Gefitinib—Alopecia—Betamethasone—multiple sclerosis	0.000199	0.00137	CcSEcCtD
Gefitinib—Diarrhoea—Azathioprine—multiple sclerosis	0.000198	0.00136	CcSEcCtD
Gefitinib—Angioedema—Triamcinolone—multiple sclerosis	0.000197	0.00136	CcSEcCtD
Gefitinib—Haemoglobin—Prednisone—multiple sclerosis	0.000197	0.00136	CcSEcCtD
Gefitinib—Angioedema—Methylprednisolone—multiple sclerosis	0.000197	0.00136	CcSEcCtD
Gefitinib—Haemorrhage—Prednisone—multiple sclerosis	0.000196	0.00135	CcSEcCtD
Gefitinib—CYP3A4—central nervous system—multiple sclerosis	0.000195	0.00247	CbGeAlD
Gefitinib—Malaise—Triamcinolone—multiple sclerosis	0.000195	0.00134	CcSEcCtD
Gefitinib—Malaise—Methylprednisolone—multiple sclerosis	0.000194	0.00134	CcSEcCtD
Gefitinib—CYP2D6—central nervous system—multiple sclerosis	0.000192	0.00243	CbGeAlD
Gefitinib—ABCB1—medulla oblongata—multiple sclerosis	0.000191	0.00242	CbGeAlD
Gefitinib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000191	0.00132	CcSEcCtD
Gefitinib—Shock—Prednisolone—multiple sclerosis	0.000188	0.0013	CcSEcCtD
Gefitinib—Cough—Triamcinolone—multiple sclerosis	0.000188	0.0013	CcSEcCtD
Gefitinib—CYP2D6—cerebellum—multiple sclerosis	0.000188	0.00238	CbGeAlD
Gefitinib—Urticaria—Mitoxantrone—multiple sclerosis	0.000185	0.00128	CcSEcCtD
Gefitinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000185	0.00127	CcSEcCtD
Gefitinib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000185	0.00127	CcSEcCtD
Gefitinib—Vomiting—Azathioprine—multiple sclerosis	0.000184	0.00127	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—multiple sclerosis	0.000183	0.00127	CcSEcCtD
Gefitinib—Eye disorder—Prednisone—multiple sclerosis	0.000183	0.00126	CcSEcCtD
Gefitinib—Infestation—Methotrexate—multiple sclerosis	0.000182	0.00126	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000182	0.00126	CcSEcCtD
Gefitinib—Rash—Azathioprine—multiple sclerosis	0.000182	0.00126	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000182	0.00126	CcSEcCtD
Gefitinib—Dermatitis—Azathioprine—multiple sclerosis	0.000182	0.00126	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000181	0.00125	CcSEcCtD
Gefitinib—Dry mouth—Triamcinolone—multiple sclerosis	0.00018	0.00124	CcSEcCtD
Gefitinib—Angioedema—Dexamethasone—multiple sclerosis	0.000179	0.00123	CcSEcCtD
Gefitinib—Angioedema—Betamethasone—multiple sclerosis	0.000179	0.00123	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—multiple sclerosis	0.000178	0.00123	CcSEcCtD
Gefitinib—Angiopathy—Prednisone—multiple sclerosis	0.000178	0.00123	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—multiple sclerosis	0.000177	0.00122	CcSEcCtD
Gefitinib—Malaise—Betamethasone—multiple sclerosis	0.000177	0.00122	CcSEcCtD
Gefitinib—Malaise—Dexamethasone—multiple sclerosis	0.000177	0.00122	CcSEcCtD
Gefitinib—Arrhythmia—Prednisone—multiple sclerosis	0.000175	0.00121	CcSEcCtD
Gefitinib—Infection—Triamcinolone—multiple sclerosis	0.000175	0.00121	CcSEcCtD
Gefitinib—Infection—Methylprednisolone—multiple sclerosis	0.000175	0.0012	CcSEcCtD
Gefitinib—ABCB1—midbrain—multiple sclerosis	0.000175	0.00221	CbGeAlD
Gefitinib—Haematuria—Methotrexate—multiple sclerosis	0.000174	0.0012	CcSEcCtD
Gefitinib—Shock—Triamcinolone—multiple sclerosis	0.000173	0.0012	CcSEcCtD
Gefitinib—Alopecia—Prednisone—multiple sclerosis	0.000173	0.00119	CcSEcCtD
Gefitinib—Shock—Methylprednisolone—multiple sclerosis	0.000173	0.00119	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000173	0.00119	CcSEcCtD
Gefitinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000172	0.00119	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—multiple sclerosis	0.000172	0.00119	CcSEcCtD
Gefitinib—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000172	0.00119	CcSEcCtD
Gefitinib—Nausea—Azathioprine—multiple sclerosis	0.000172	0.00118	CcSEcCtD
Gefitinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000171	0.00118	CcSEcCtD
Gefitinib—Malnutrition—Prednisone—multiple sclerosis	0.000171	0.00118	CcSEcCtD
Gefitinib—ABCB1—spinal cord—multiple sclerosis	0.00017	0.00216	CbGeAlD
Gefitinib—Asthenia—Mitoxantrone—multiple sclerosis	0.000168	0.00116	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—multiple sclerosis	0.000165	0.00114	CcSEcCtD
Gefitinib—Hypotension—Methylprednisolone—multiple sclerosis	0.000164	0.00113	CcSEcCtD
Gefitinib—Pain—Prednisolone—multiple sclerosis	0.000164	0.00113	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—multiple sclerosis	0.000164	0.00113	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—multiple sclerosis	0.000164	0.00113	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000162	0.00112	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—multiple sclerosis	0.000161	0.00111	CcSEcCtD
Gefitinib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00016	0.0011	CcSEcCtD
Gefitinib—Infection—Dexamethasone—multiple sclerosis	0.000159	0.0011	CcSEcCtD
Gefitinib—Infection—Betamethasone—multiple sclerosis	0.000159	0.0011	CcSEcCtD
Gefitinib—Anaemia—Prednisone—multiple sclerosis	0.000158	0.00109	CcSEcCtD
Gefitinib—Shock—Dexamethasone—multiple sclerosis	0.000157	0.00109	CcSEcCtD
Gefitinib—Shock—Betamethasone—multiple sclerosis	0.000157	0.00109	CcSEcCtD
Gefitinib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000157	0.00108	CcSEcCtD
Gefitinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000157	0.00108	CcSEcCtD
Gefitinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000157	0.00108	CcSEcCtD
Gefitinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000157	0.00108	CcSEcCtD
Gefitinib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000157	0.00108	CcSEcCtD
Gefitinib—Angioedema—Prednisone—multiple sclerosis	0.000156	0.00108	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—multiple sclerosis	0.000155	0.00107	CcSEcCtD
Gefitinib—Malaise—Prednisone—multiple sclerosis	0.000154	0.00106	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—multiple sclerosis	0.000153	0.00106	CcSEcCtD
Gefitinib—CYP2D6—brain—multiple sclerosis	0.000153	0.00193	CbGeAlD
Gefitinib—Anorexia—Dexamethasone—multiple sclerosis	0.000152	0.00105	CcSEcCtD
Gefitinib—Anorexia—Betamethasone—multiple sclerosis	0.000152	0.00105	CcSEcCtD
Gefitinib—Urticaria—Prednisolone—multiple sclerosis	0.000152	0.00105	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000152	0.00105	CcSEcCtD
Gefitinib—Fatigue—Triamcinolone—multiple sclerosis	0.000152	0.00105	CcSEcCtD
Gefitinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000152	0.00105	CcSEcCtD
Gefitinib—Pain—Triamcinolone—multiple sclerosis	0.000151	0.00104	CcSEcCtD
Gefitinib—Hypotension—Betamethasone—multiple sclerosis	0.000149	0.00103	CcSEcCtD
Gefitinib—Hypotension—Dexamethasone—multiple sclerosis	0.000149	0.00103	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—multiple sclerosis	0.000149	0.00103	CcSEcCtD
Gefitinib—Vomiting—Mitoxantrone—multiple sclerosis	0.000148	0.00102	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000148	0.00102	CcSEcCtD
Gefitinib—Rash—Mitoxantrone—multiple sclerosis	0.000147	0.00102	CcSEcCtD
Gefitinib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000147	0.00101	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—multiple sclerosis	0.000145	0.000998	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000144	0.000995	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000144	0.000992	CcSEcCtD
Gefitinib—ABCB1—nervous system—multiple sclerosis	0.000144	0.00182	CbGeAlD
Gefitinib—Malnutrition—Methotrexate—multiple sclerosis	0.000143	0.000984	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisolone—multiple sclerosis	0.000141	0.000974	CcSEcCtD
Gefitinib—Urticaria—Triamcinolone—multiple sclerosis	0.00014	0.000966	CcSEcCtD
Gefitinib—Urticaria—Methylprednisolone—multiple sclerosis	0.00014	0.000964	CcSEcCtD
Gefitinib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000139	0.000961	CcSEcCtD
Gefitinib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000139	0.000959	CcSEcCtD
Gefitinib—Decreased appetite—Betamethasone—multiple sclerosis	0.000139	0.000959	CcSEcCtD
Gefitinib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000139	0.000959	CcSEcCtD
Gefitinib—Nausea—Mitoxantrone—multiple sclerosis	0.000139	0.000957	CcSEcCtD
Gefitinib—Infection—Prednisone—multiple sclerosis	0.000138	0.000954	CcSEcCtD
Gefitinib—ABCB1—central nervous system—multiple sclerosis	0.000138	0.00175	CbGeAlD
Gefitinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000138	0.000952	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000138	0.000952	CcSEcCtD
Gefitinib—Fatigue—Dexamethasone—multiple sclerosis	0.000138	0.000951	CcSEcCtD
Gefitinib—Fatigue—Betamethasone—multiple sclerosis	0.000138	0.000951	CcSEcCtD
Gefitinib—Shock—Prednisone—multiple sclerosis	0.000137	0.000945	CcSEcCtD
Gefitinib—Pain—Dexamethasone—multiple sclerosis	0.000137	0.000943	CcSEcCtD
Gefitinib—Pain—Betamethasone—multiple sclerosis	0.000137	0.000943	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—multiple sclerosis	0.000137	0.000942	CcSEcCtD
Gefitinib—Skin disorder—Prednisone—multiple sclerosis	0.000135	0.000933	CcSEcCtD
Gefitinib—ABCB1—cerebellum—multiple sclerosis	0.000135	0.00171	CbGeAlD
Gefitinib—Anorexia—Prednisone—multiple sclerosis	0.000133	0.000916	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—multiple sclerosis	0.000132	0.000909	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000131	0.000902	CcSEcCtD
Gefitinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000131	0.000902	CcSEcCtD
Gefitinib—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00013	0.000896	CcSEcCtD
Gefitinib—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000129	0.000894	CcSEcCtD
Gefitinib—Malaise—Methotrexate—multiple sclerosis	0.000129	0.000887	CcSEcCtD
Gefitinib—Urticaria—Dexamethasone—multiple sclerosis	0.000127	0.000876	CcSEcCtD
Gefitinib—Urticaria—Betamethasone—multiple sclerosis	0.000127	0.000876	CcSEcCtD
Gefitinib—Asthenia—Triamcinolone—multiple sclerosis	0.000126	0.000872	CcSEcCtD
Gefitinib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000126	0.000872	CcSEcCtD
Gefitinib—Body temperature increased—Betamethasone—multiple sclerosis	0.000126	0.000872	CcSEcCtD
Gefitinib—Abdominal pain—Betamethasone—multiple sclerosis	0.000126	0.000872	CcSEcCtD
Gefitinib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000126	0.000872	CcSEcCtD
Gefitinib—Asthenia—Methylprednisolone—multiple sclerosis	0.000126	0.00087	CcSEcCtD
Gefitinib—Pruritus—Triamcinolone—multiple sclerosis	0.000125	0.00086	CcSEcCtD
Gefitinib—Cough—Methotrexate—multiple sclerosis	0.000124	0.000858	CcSEcCtD
Gefitinib—Pruritus—Methylprednisolone—multiple sclerosis	0.000124	0.000858	CcSEcCtD
Gefitinib—Decreased appetite—Prednisone—multiple sclerosis	0.000121	0.000835	CcSEcCtD
Gefitinib—Rash—Prednisolone—multiple sclerosis	0.000121	0.000833	CcSEcCtD
Gefitinib—Dermatitis—Prednisolone—multiple sclerosis	0.000121	0.000833	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000121	0.000832	CcSEcCtD
Gefitinib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00012	0.00083	CcSEcCtD
Gefitinib—Fatigue—Prednisone—multiple sclerosis	0.00012	0.000828	CcSEcCtD
Gefitinib—Constipation—Prednisone—multiple sclerosis	0.000119	0.000821	CcSEcCtD
Gefitinib—Infection—Methotrexate—multiple sclerosis	0.000116	0.000798	CcSEcCtD
Gefitinib—Asthenia—Betamethasone—multiple sclerosis	0.000115	0.000791	CcSEcCtD
Gefitinib—Asthenia—Dexamethasone—multiple sclerosis	0.000115	0.000791	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000114	0.000787	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000114	0.000786	CcSEcCtD
Gefitinib—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000114	0.000785	CcSEcCtD
Gefitinib—Nausea—Prednisolone—multiple sclerosis	0.000114	0.000785	CcSEcCtD
Gefitinib—Pruritus—Betamethasone—multiple sclerosis	0.000113	0.00078	CcSEcCtD
Gefitinib—Pruritus—Dexamethasone—multiple sclerosis	0.000113	0.00078	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—multiple sclerosis	0.000113	0.00078	CcSEcCtD
Gefitinib—Vomiting—Triamcinolone—multiple sclerosis	0.000112	0.000773	CcSEcCtD
Gefitinib—Vomiting—Methylprednisolone—multiple sclerosis	0.000112	0.000771	CcSEcCtD
Gefitinib—Rash—Triamcinolone—multiple sclerosis	0.000111	0.000766	CcSEcCtD
Gefitinib—Dermatitis—Triamcinolone—multiple sclerosis	0.000111	0.000766	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—multiple sclerosis	0.000111	0.000765	CcSEcCtD
Gefitinib—Rash—Methylprednisolone—multiple sclerosis	0.000111	0.000765	CcSEcCtD
Gefitinib—Dermatitis—Methylprednisolone—multiple sclerosis	0.000111	0.000764	CcSEcCtD
Gefitinib—Urticaria—Prednisone—multiple sclerosis	0.000111	0.000763	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—multiple sclerosis	0.00011	0.000759	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—multiple sclerosis	0.00011	0.000759	CcSEcCtD
Gefitinib—ABCB1—brain—multiple sclerosis	0.00011	0.00139	CbGeAlD
Gefitinib—Diarrhoea—Betamethasone—multiple sclerosis	0.000109	0.000755	CcSEcCtD
Gefitinib—Diarrhoea—Dexamethasone—multiple sclerosis	0.000109	0.000755	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—multiple sclerosis	0.000109	0.00075	CcSEcCtD
Gefitinib—Nausea—Triamcinolone—multiple sclerosis	0.000105	0.000722	CcSEcCtD
Gefitinib—Nausea—Methylprednisolone—multiple sclerosis	0.000104	0.00072	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—multiple sclerosis	0.000104	0.000716	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisone—multiple sclerosis	0.000103	0.000708	CcSEcCtD
Gefitinib—Vomiting—Betamethasone—multiple sclerosis	0.000102	0.000701	CcSEcCtD
Gefitinib—Vomiting—Dexamethasone—multiple sclerosis	0.000102	0.000701	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—multiple sclerosis	0.000101	0.000698	CcSEcCtD
Gefitinib—Rash—Dexamethasone—multiple sclerosis	0.000101	0.000695	CcSEcCtD
Gefitinib—Rash—Betamethasone—multiple sclerosis	0.000101	0.000695	CcSEcCtD
Gefitinib—Dermatitis—Betamethasone—multiple sclerosis	0.000101	0.000695	CcSEcCtD
Gefitinib—Dermatitis—Dexamethasone—multiple sclerosis	0.000101	0.000695	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.0001	0.000693	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—multiple sclerosis	0.0001	0.000692	CcSEcCtD
Gefitinib—Asthenia—Prednisone—multiple sclerosis	9.99e-05	0.000689	CcSEcCtD
Gefitinib—Pain—Methotrexate—multiple sclerosis	9.95e-05	0.000686	CcSEcCtD
Gefitinib—Pruritus—Prednisone—multiple sclerosis	9.85e-05	0.00068	CcSEcCtD
Gefitinib—Diarrhoea—Prednisone—multiple sclerosis	9.52e-05	0.000657	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	9.51e-05	0.000656	CcSEcCtD
Gefitinib—Nausea—Betamethasone—multiple sclerosis	9.49e-05	0.000655	CcSEcCtD
Gefitinib—Nausea—Dexamethasone—multiple sclerosis	9.49e-05	0.000655	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—multiple sclerosis	9.24e-05	0.000638	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—multiple sclerosis	9.2e-05	0.000635	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—multiple sclerosis	9.2e-05	0.000635	CcSEcCtD
Gefitinib—Vomiting—Prednisone—multiple sclerosis	8.85e-05	0.000611	CcSEcCtD
Gefitinib—Rash—Prednisone—multiple sclerosis	8.78e-05	0.000606	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—multiple sclerosis	8.77e-05	0.000605	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—multiple sclerosis	8.57e-05	0.000591	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—multiple sclerosis	8.35e-05	0.000576	CcSEcCtD
Gefitinib—Nausea—Prednisone—multiple sclerosis	8.27e-05	0.000571	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—multiple sclerosis	8.23e-05	0.000568	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—multiple sclerosis	7.96e-05	0.000549	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—multiple sclerosis	7.4e-05	0.00051	CcSEcCtD
Gefitinib—Rash—Methotrexate—multiple sclerosis	7.34e-05	0.000506	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—multiple sclerosis	7.33e-05	0.000506	CcSEcCtD
Gefitinib—Nausea—Methotrexate—multiple sclerosis	6.91e-05	0.000477	CcSEcCtD
Gefitinib—MKNK1—Disease—MAPK1—multiple sclerosis	1.48e-05	9.99e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	1.47e-05	9.94e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD80—multiple sclerosis	1.47e-05	9.93e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCL5—multiple sclerosis	1.45e-05	9.81e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCR5—multiple sclerosis	1.44e-05	9.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MAPK1—multiple sclerosis	1.44e-05	9.72e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SPP1—multiple sclerosis	1.43e-05	9.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—TYK2—multiple sclerosis	1.42e-05	9.63e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—POMC—multiple sclerosis	1.42e-05	9.62e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2RA—multiple sclerosis	1.42e-05	9.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SRM—multiple sclerosis	1.42e-05	9.58e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—RRM1—multiple sclerosis	1.4e-05	9.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DQB1—multiple sclerosis	1.4e-05	9.46e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.4e-05	9.44e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IFNG—multiple sclerosis	1.4e-05	9.43e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCL2—multiple sclerosis	1.39e-05	9.41e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCR5—multiple sclerosis	1.39e-05	9.38e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.38e-05	9.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TYK2—multiple sclerosis	1.38e-05	9.3e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2RA—multiple sclerosis	1.37e-05	9.24e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—MAPK1—multiple sclerosis	1.36e-05	9.16e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL2—multiple sclerosis	1.35e-05	9.15e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD4—multiple sclerosis	1.35e-05	9.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD86—multiple sclerosis	1.35e-05	9.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL3—multiple sclerosis	1.33e-05	8.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD40LG—multiple sclerosis	1.32e-05	8.93e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.31e-05	8.87e-05	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.31e-05	8.87e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—APOE—multiple sclerosis	1.31e-05	8.85e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—STAT3—multiple sclerosis	1.31e-05	8.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCR5—multiple sclerosis	1.31e-05	8.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—multiple sclerosis	1.31e-05	8.83e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—BCHE—multiple sclerosis	1.3e-05	8.82e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CD86—multiple sclerosis	1.3e-05	8.8e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2RA—multiple sclerosis	1.29e-05	8.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2RA—multiple sclerosis	1.29e-05	8.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD4—multiple sclerosis	1.29e-05	8.71e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL5—multiple sclerosis	1.28e-05	8.67e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—multiple sclerosis	1.28e-05	8.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTGER4—multiple sclerosis	1.28e-05	8.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—multiple sclerosis	1.27e-05	8.59e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TYK2—multiple sclerosis	1.26e-05	8.55e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—STAT3—multiple sclerosis	1.26e-05	8.55e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—APOE—multiple sclerosis	1.26e-05	8.53e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.26e-05	8.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-B—multiple sclerosis	1.26e-05	8.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PGR—multiple sclerosis	1.26e-05	8.49e-05	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IL6—multiple sclerosis	1.25e-05	8.46e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1B—multiple sclerosis	1.24e-05	8.41e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD4—multiple sclerosis	1.24e-05	8.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD86—multiple sclerosis	1.24e-05	8.41e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—TYK2—multiple sclerosis	1.24e-05	8.39e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL2—multiple sclerosis	1.24e-05	8.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD4—multiple sclerosis	1.24e-05	8.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCR3—multiple sclerosis	1.23e-05	8.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—RRM1—multiple sclerosis	1.23e-05	8.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—IL6—multiple sclerosis	1.22e-05	8.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CD28—multiple sclerosis	1.22e-05	8.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCR2—multiple sclerosis	1.2e-05	8.1e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.19e-05	8.06e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—MAPK1—multiple sclerosis	1.19e-05	8.04e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SPP1—multiple sclerosis	1.19e-05	8.03e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CD80—multiple sclerosis	1.18e-05	8e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2RA—multiple sclerosis	1.18e-05	7.96e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MYC—multiple sclerosis	1.17e-05	7.94e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—TGFB1—multiple sclerosis	1.17e-05	7.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-A—multiple sclerosis	1.16e-05	7.87e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IFNG—multiple sclerosis	1.16e-05	7.85e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.16e-05	7.82e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCR5—multiple sclerosis	1.15e-05	7.81e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MAPK1—multiple sclerosis	1.15e-05	7.77e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.15e-05	7.76e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.15e-05	7.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CD80—multiple sclerosis	1.14e-05	7.71e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2RA—multiple sclerosis	1.14e-05	7.7e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—STAT3—multiple sclerosis	1.14e-05	7.7e-05	CbGpPWpGaD
Gefitinib—MKNK1—Disease—IL6—multiple sclerosis	1.14e-05	7.68e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.13e-05	7.66e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.13e-05	7.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—STAT3—multiple sclerosis	1.13e-05	7.63e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.13e-05	7.61e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—POMC—multiple sclerosis	1.12e-05	7.6e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD4—multiple sclerosis	1.12e-05	7.58e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.11e-05	7.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CNR1—multiple sclerosis	1.11e-05	7.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—multiple sclerosis	1.11e-05	7.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CCR5—multiple sclerosis	1.1e-05	7.46e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCL2—multiple sclerosis	1.1e-05	7.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.09e-05	7.35e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—POMC—multiple sclerosis	1.08e-05	7.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HLA-A—multiple sclerosis	1.07e-05	7.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—TLR4—multiple sclerosis	1.06e-05	7.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DRB1—multiple sclerosis	1.06e-05	7.19e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCL2—multiple sclerosis	1.06e-05	7.17e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MYC—multiple sclerosis	1.06e-05	7.15e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TGFB1—multiple sclerosis	1.06e-05	7.13e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.05e-05	7.13e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL2—multiple sclerosis	1.05e-05	7.11e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—APOE—multiple sclerosis	1.05e-05	7.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TGFB1—multiple sclerosis	1.05e-05	7.08e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—STAT3—multiple sclerosis	1.04e-05	7.05e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—multiple sclerosis	1.04e-05	7.04e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1B—multiple sclerosis	1.04e-05	7e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MAPK1—multiple sclerosis	1.03e-05	7e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL2—multiple sclerosis	1.03e-05	6.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MAPK1—multiple sclerosis	1.03e-05	6.94e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.02e-05	6.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—POMC—multiple sclerosis	1.02e-05	6.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ICAM1—multiple sclerosis	1.02e-05	6.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—APOE—multiple sclerosis	1e-05	6.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCL2—multiple sclerosis	1e-05	6.76e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TYK2—multiple sclerosis	9.99e-06	6.76e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	9.98e-06	6.75e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	9.98e-06	6.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL10—multiple sclerosis	9.96e-06	6.73e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—multiple sclerosis	9.96e-06	6.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD80—multiple sclerosis	9.83e-06	6.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—multiple sclerosis	9.77e-06	6.61e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.76e-06	6.6e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TYK2—multiple sclerosis	9.63e-06	6.51e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—STAT3—multiple sclerosis	9.63e-06	6.51e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CD80—multiple sclerosis	9.5e-06	6.42e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MAPK1—multiple sclerosis	9.48e-06	6.41e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—BCHE—multiple sclerosis	9.34e-06	6.32e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.34e-06	6.31e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.34e-06	6.31e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—multiple sclerosis	9.14e-06	6.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	9.13e-06	6.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—TYK2—multiple sclerosis	9.08e-06	6.14e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD80—multiple sclerosis	9.07e-06	6.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MAPK1—multiple sclerosis	9.06e-06	6.13e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—POMC—multiple sclerosis	9.03e-06	6.1e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MYC—multiple sclerosis	8.95e-06	6.05e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFB1—multiple sclerosis	8.93e-06	6.04e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.9e-06	6.01e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—STAT3—multiple sclerosis	8.85e-06	5.98e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL2—multiple sclerosis	8.83e-06	5.97e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—multiple sclerosis	8.83e-06	5.97e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—BCHE—multiple sclerosis	8.83e-06	5.97e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MAPK1—multiple sclerosis	8.76e-06	5.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CD86—multiple sclerosis	8.71e-06	5.89e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—STAT3—multiple sclerosis	8.69e-06	5.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL5—multiple sclerosis	8.57e-06	5.8e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.38e-06	5.67e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2—multiple sclerosis	8.32e-06	5.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—TYK2—multiple sclerosis	8.29e-06	5.61e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MYC—multiple sclerosis	8.23e-06	5.56e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TGFB1—multiple sclerosis	8.21e-06	5.55e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MAPK1—multiple sclerosis	8.05e-06	5.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—BCHE—multiple sclerosis	8.05e-06	5.44e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TYK2—multiple sclerosis	8.02e-06	5.42e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2—multiple sclerosis	8.02e-06	5.42e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—multiple sclerosis	7.95e-06	5.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SPP1—multiple sclerosis	7.94e-06	5.37e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MAPK1—multiple sclerosis	7.9e-06	5.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—multiple sclerosis	7.89e-06	5.33e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—multiple sclerosis	7.87e-06	5.32e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—APOE—multiple sclerosis	7.84e-06	5.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFNG—multiple sclerosis	7.77e-06	5.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCR5—multiple sclerosis	7.72e-06	5.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TYK2—multiple sclerosis	7.66e-06	5.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.64e-06	5.17e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.64e-06	5.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2RA—multiple sclerosis	7.61e-06	5.15e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—multiple sclerosis	7.59e-06	5.13e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2—multiple sclerosis	7.58e-06	5.13e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	7.56e-06	5.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2—multiple sclerosis	7.55e-06	5.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD4—multiple sclerosis	7.5e-06	5.07e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—multiple sclerosis	7.29e-06	4.93e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—BCHE—multiple sclerosis	7.22e-06	4.88e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.09e-06	4.79e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—BCHE—multiple sclerosis	7.05e-06	4.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOE—multiple sclerosis	7.03e-06	4.75e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STAT3—multiple sclerosis	7e-06	4.73e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.97e-06	4.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—multiple sclerosis	6.97e-06	4.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—multiple sclerosis	6.93e-06	4.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD4—multiple sclerosis	6.93e-06	4.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—multiple sclerosis	6.9e-06	4.67e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—multiple sclerosis	6.74e-06	4.56e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—POMC—multiple sclerosis	6.74e-06	4.56e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—multiple sclerosis	6.73e-06	4.55e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—multiple sclerosis	6.67e-06	4.51e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—BCHE—multiple sclerosis	6.64e-06	4.49e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—BCHE—multiple sclerosis	6.59e-06	4.45e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—multiple sclerosis	6.5e-06	4.4e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—multiple sclerosis	6.49e-06	4.39e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK1—multiple sclerosis	6.36e-06	4.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CD80—multiple sclerosis	6.35e-06	4.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—multiple sclerosis	6.32e-06	4.27e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—multiple sclerosis	6.27e-06	4.24e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—multiple sclerosis	6.25e-06	4.23e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—multiple sclerosis	6.18e-06	4.18e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—multiple sclerosis	6.14e-06	4.15e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK1—multiple sclerosis	6.13e-06	4.15e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—multiple sclerosis	6.07e-06	4.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—POMC—multiple sclerosis	6.04e-06	4.08e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—multiple sclerosis	5.91e-06	4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—multiple sclerosis	5.91e-06	3.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—multiple sclerosis	5.81e-06	3.93e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK1—multiple sclerosis	5.8e-06	3.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK1—multiple sclerosis	5.78e-06	3.91e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—multiple sclerosis	5.62e-06	3.8e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—multiple sclerosis	5.62e-06	3.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TYK2—multiple sclerosis	5.36e-06	3.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—multiple sclerosis	5.36e-06	3.63e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—multiple sclerosis	5.31e-06	3.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK1—multiple sclerosis	5.28e-06	3.57e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—multiple sclerosis	5.22e-06	3.53e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—multiple sclerosis	5.21e-06	3.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK1—multiple sclerosis	5.1e-06	3.45e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—multiple sclerosis	4.98e-06	3.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—multiple sclerosis	4.97e-06	3.36e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—multiple sclerosis	4.89e-06	3.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK1—multiple sclerosis	4.87e-06	3.3e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—multiple sclerosis	4.84e-06	3.27e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—POMC—multiple sclerosis	4.83e-06	3.26e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—multiple sclerosis	4.71e-06	3.19e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—POMC—multiple sclerosis	4.56e-06	3.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—multiple sclerosis	4.46e-06	3.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—multiple sclerosis	4.44e-06	3e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—multiple sclerosis	4.4e-06	2.98e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—multiple sclerosis	4.35e-06	2.94e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	4.34e-06	2.94e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—multiple sclerosis	4.24e-06	2.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—multiple sclerosis	4.22e-06	2.86e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—multiple sclerosis	4.16e-06	2.81e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—POMC—multiple sclerosis	4.16e-06	2.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—multiple sclerosis	4.06e-06	2.74e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—multiple sclerosis	4e-06	2.7e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—multiple sclerosis	3.96e-06	2.68e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—multiple sclerosis	3.92e-06	2.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—multiple sclerosis	3.76e-06	2.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—multiple sclerosis	3.75e-06	2.53e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—POMC—multiple sclerosis	3.73e-06	2.52e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—POMC—multiple sclerosis	3.64e-06	2.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—multiple sclerosis	3.49e-06	2.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—multiple sclerosis	3.48e-06	2.35e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—POMC—multiple sclerosis	3.43e-06	2.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK1—multiple sclerosis	3.41e-06	2.31e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—POMC—multiple sclerosis	3.4e-06	2.3e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—multiple sclerosis	3.4e-06	2.3e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—multiple sclerosis	3.32e-06	2.25e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—multiple sclerosis	3.13e-06	2.12e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—multiple sclerosis	3.1e-06	2.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—multiple sclerosis	2.62e-06	1.77e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—multiple sclerosis	2.61e-06	1.77e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—POMC—multiple sclerosis	2.24e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—multiple sclerosis	2.05e-06	1.38e-05	CbGpPWpGaD
